Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744288 · ClinicalTrials.gov registry record · Phase 1
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
A Phase 1 study of Inhibition on Platelet Aggregation, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
- 1
- Study location
NCT01744288: Completed Phase 1 study of Inhibition on Platelet Aggregation, sponsored by AstraZeneca.
NCT01744288 is a Phase 1 study of Inhibition on Platelet Aggregation that has completed, run by AstraZeneca. The registered enrollment target is 258 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (330% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01744288, a Phase 1 study of Inhibition on Platelet Aggregation, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Ticagrelor
- DRUG ASA
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT01744288 record still lists
NCT01744288 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (330% higher).
The record links to 1 condition, with Inhibition on Platelet Aggregation appearing as the primary indexed condition, and to 3 interventions - of which Clopidogrel is the first listed.
NCT01744288 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01744288 about?
NCT01744288 is a clinical study titled "Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets". Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
What is the current status of trial NCT01744288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2012-12. Estimated completion is 2014-04.
What conditions does trial NCT01744288 study?
This clinical trial studies the following conditions: Inhibition on Platelet Aggregation.
What interventions are being tested in trial NCT01744288?
The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG), ASA (DRUG).
Who is sponsoring clinical trial NCT01744288?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01744288 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01744288's enrollment target sits among peer trials
258 167th of 2000 higher than 1,833 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia